Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients - PubMed (original) (raw)
Clinical Trial
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients
F Baskin et al. Neurology. 2003.
Abstract
Platelets, like neurons, contain 120- to 130- and 110-kd amyloid precursor proteins (APPs). Their ratio is reduced in AD, further reductions correlating with reduced Mini-Mental Status Examination scores [r(11) = 0.69, p < 0.05]. As statins alter APP processing, platelet APPs were analyzed in patients with AD given anticholesterol drugs for 6 weeks. APP ratios increased [t(37) = -3.888, p = 0.0004], proportionally with reduced cholesterol [r(36) = -0.45, p = 0.005]. Longer trials may reveal slowed cognitive loss, validating this index.
Similar articles
- Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, Svetlik D. Vega GL, et al. Arch Neurol. 2003 Apr;60(4):510-5. doi: 10.1001/archneur.60.4.510. Arch Neurol. 2003. PMID: 12707064 Clinical Trial. - Platelet APP isoform ratios correlate with declining cognition in AD.
Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM. Baskin F, et al. Neurology. 2000 May 23;54(10):1907-9. doi: 10.1212/wnl.54.10.1907. Neurology. 2000. PMID: 10822427 - Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.
Sotiriou CG, Cheng JW. Sotiriou CG, et al. Ann Pharmacother. 2000 Dec;34(12):1432-9. doi: 10.1345/aph.10124. Ann Pharmacother. 2000. PMID: 11144702 Review. - Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER. Riekse RG, et al. J Alzheimers Dis. 2006 Dec;10(4):399-406. doi: 10.3233/jad-2006-10408. J Alzheimers Dis. 2006. PMID: 17183151 Clinical Trial. - [Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Sinzinger H. Sinzinger H. Dtsch Med Wochenschr. 1998 Sep 18;123(38):1116-22. doi: 10.1055/s-2007-1024133. Dtsch Med Wochenschr. 1998. PMID: 9787294 Review. German. No abstract available.
Cited by
- Biological marker candidates of Alzheimer's disease in blood, plasma, and serum.
Schneider P, Hampel H, Buerger K. Schneider P, et al. CNS Neurosci Ther. 2009 Winter;15(4):358-74. doi: 10.1111/j.1755-5949.2009.00104.x. Epub 2009 Oct 14. CNS Neurosci Ther. 2009. PMID: 19840034 Free PMC article. Review. - Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease.
Tang K, Hynan LS, Baskin F, Rosenberg RN. Tang K, et al. J Neurol Sci. 2006 Jan 15;240(1-2):53-8. doi: 10.1016/j.jns.2005.09.002. Epub 2005 Oct 26. J Neurol Sci. 2006. PMID: 16256140 Free PMC article. - Biomarkers of Alzheimer disease in plasma.
Irizarry MC. Irizarry MC. NeuroRx. 2004 Apr;1(2):226-34. doi: 10.1602/neurorx.1.2.226. NeuroRx. 2004. PMID: 15717023 Free PMC article. Review. - Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimer's Disease? A Systematic Review.
Carbone MG, Pagni G, Tagliarini C, Marazziti D, Pomara N. Carbone MG, et al. Life (Basel). 2021 Jul 26;11(8):750. doi: 10.3390/life11080750. Life (Basel). 2021. PMID: 34440494 Free PMC article. Review. - Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.
Noelker C, Hampel H, Dodel R. Noelker C, et al. Mol Diagn Ther. 2011 Apr 1;15(2):83-102. doi: 10.1007/BF03256398. Mol Diagn Ther. 2011. PMID: 21623645 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials